Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.800
0.00 (0.00%)
At close: Oct 2, 2025, 4:00 PM EDT
1.818
+0.018 (1.02%)
After-hours: Oct 2, 2025, 7:04 PM EDT
Opus Genetics Revenue
Opus Genetics had revenue of $2.88M in the quarter ending June 30, 2025, with 159.17% growth. This brings the company's revenue in the last twelve months to $15.42M, down -6.25% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$15.42M
Revenue Growth
-6.25%
P/S Ratio
4.49
Revenue / Employee
$856,722
Employees
18
Market Cap
113.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
Dec 31, 2021 | 589.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IRD News
- 16 hours ago - Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 - GlobeNewsWire
- 2 days ago - Opus Genetics, Inc. - Special Call - Seeking Alpha
- 2 days ago - Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) - GlobeNewsWire
- 20 days ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 4 weeks ago - Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Opus Genetics Appoints Rob Gagnon as Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September - GlobeNewsWire